<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587791</url>
  </required_header>
  <id_info>
    <org_study_id>JD001</org_study_id>
    <secondary_id>2000029286</secondary_id>
    <secondary_id>1K23DA052682-01</secondary_id>
    <nct_id>NCT04587791</nct_id>
  </id_info>
  <brief_title>Cannabidiol in Opioid Use Disorder and Chronic Pain</brief_title>
  <official_title>Cannabidiol Pharmacotherapy for Co-occurring Opioid Use Disorder and Chronic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Connecticut Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled cross-over human laboratory study with&#xD;
      a duration of approximately 3 weeks, during which participants will come to the testing site&#xD;
      for a total of five times: one initial screening session, and four experimental sessions&#xD;
      where study medication, Cannabidiol (CBD) will be administered, separated by at least 72&#xD;
      hours to limit carryover effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty two male and female (ages 18-70) participants with comorbid opioid use disorder (OUD)&#xD;
      and non-cancer chronic pain for at least 6 months, currently receiving methadone or&#xD;
      buprenorphine, will be enrolled. Prior to their daily methadone or buprenorphine dose and&#xD;
      thus at trough plasma levels of opioid, participants will receive oral CBD (400 mg, 800 mg,&#xD;
      1200 mg) or placebo. Subsequently, all participants will undergo laboratory testing of&#xD;
      opioid-related outcomes.&#xD;
&#xD;
      Pain sensitivity will be measures including the well-validated Cold Pressor Test (CPT),&#xD;
      Quantitative Sensory Testing (QST), the Short-Form McGill Pain Questionnaire (SF-MPQ) and a&#xD;
      pain Visual Analog Scale (VAS). Attentional bias and cue-induced opioid craving will be&#xD;
      measured using a visual probe task and the Heroin Craving Scale (HCQ-14). Negative affect&#xD;
      will be measured using the Positive and Negative Affect Schedule (PANAS). Cognitive&#xD;
      performance will be measured by a comprehensive cognitive battery that includes the&#xD;
      Continuous Performance Test (CPT) and the Hopkins Verbal Learning Test (HVLT). The order of&#xD;
      study medication administration will be counterbalanced order to minimize carryover effects.&#xD;
      On the initial screening day and at the end of medication treatment, blood will be drawn to&#xD;
      determine serum drug levels. Participants will be thoroughly evaluated by a physician prior&#xD;
      to discharge on each experimental session. One week after the last study medication dose,&#xD;
      participants will be conducted by phone for a follow-up session.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>participants will receive CBD (400 mg, 800 mg, 1200 mg) or placebo.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>participants will receive CBD (400 mg, 800 mg, 1200 mg) or placebo.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SAFTEE will be used to assess the safety of CBD</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Safety of CBD will be assessed with: the SAFTEE for adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain and threshold measure by the Cold Pressor Test (CPT)</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>Pain from cold pressure test</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>CBD 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBD 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD 800mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBD 800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBD 1200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBD 1200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400mg Cannabidiol</intervention_name>
    <description>Participants will receive 400mg</description>
    <arm_group_label>CBD 400mg</arm_group_label>
    <other_name>CBD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800mg Cannabidiol</intervention_name>
    <description>Participants will receive 800mg</description>
    <arm_group_label>CBD 800mg</arm_group_label>
    <other_name>CBD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1200mg Cannabidiol</intervention_name>
    <description>Participants will receive 1200mg</description>
    <arm_group_label>CBD 1200mg</arm_group_label>
    <other_name>CBD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Participants will receive saline</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, Veterans and non-Veterans, aged between 18 and 70 years old.&#xD;
&#xD;
          -  Diagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance&#xD;
             treatment.&#xD;
&#xD;
          -  Having chronic pain, uniformly operationalized as grade II (high-intensity) non-cancer&#xD;
             musculoskeletal pain for ≥ 6 months 49&#xD;
&#xD;
          -  Capable of providing informed consent in English.&#xD;
&#xD;
          -  Compliant in opioid maintenance treatment and on a stable dose for two weeks or&#xD;
             longer.&#xD;
&#xD;
          -  Not meeting DSM-5 criteria for substance use disorders other than OUD or tobacco use&#xD;
             disorder within the last 12 months.&#xD;
&#xD;
          -  No current medical problems deemed contraindicated for participation by principal&#xD;
             investigator.&#xD;
&#xD;
          -  For women, not pregnant as determined by pregnancy screening; not breast-feeding;&#xD;
             using acceptable birth control methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other current major psychiatric disorders deemed clinically unstable by the principal&#xD;
             investigator, such as severe depression and/or active suicidal ideation.&#xD;
&#xD;
          -  Having experienced major psychosocial stressors recently (≤ 6 weeks before&#xD;
             enrollment), at the discretion of the principal investigator.&#xD;
&#xD;
          -  Having received inpatient psychiatric treatment recently (≤ 60 days before&#xD;
             enrollment).&#xD;
&#xD;
          -  A study physician will determine if participants receiving products containing THC or&#xD;
             CBD products may participate in the study.&#xD;
&#xD;
          -  Current use benzodiazepines or platelet inhibitors (e.g., clopidogrel, apixaban,&#xD;
             ticagrelor).&#xD;
&#xD;
          -  Current weight of less of 60 kg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joao De'Aquino, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joao De'Aquino, M.D.</last_name>
    <phone>203-5711</phone>
    <phone_ext>2916</phone_ext>
    <email>joao.dequino@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Mitchell, R.N.</last_name>
    <phone>203-932-5711</phone>
    <phone_ext>3012</phone_ext>
    <email>ellen.mitchell@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Veterans Affairs Hospital</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joao De'Aquino, M.D.</last_name>
      <phone>203-932-5711</phone>
      <phone_ext>3012</phone_ext>
      <email>joao.dequino@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Joao De'Aquino, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Joao De Aquino</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

